BIOMARKERS, NEOANGIOGENESIS AND GROWTH FACTORS IN PANCREATIC CANCER

Pancreatic cancer (PC) is a lethal malignant tumor characterized by a rapid progression, invasiveness and resistance to radiochemotherapy. The development of biomarkers for the early diagnosis of the disease is relevant. Angiogenesis has been identified as a key factor in a number of pathological co...

Full description

Bibliographic Details
Main Authors: E. M. Frantsiyants, O. I. Kit, V. I. Aleynov, I. A. Goroshinskaya
Format: Article
Language:Russian
Published: QUASAR, LLC 2019-09-01
Series:Issledovaniâ i Praktika v Medicine
Subjects:
Online Access:https://www.rpmj.ru/rpmj/article/view/421
_version_ 1797874077501751296
author E. M. Frantsiyants
O. I. Kit
V. I. Aleynov
I. A. Goroshinskaya
author_facet E. M. Frantsiyants
O. I. Kit
V. I. Aleynov
I. A. Goroshinskaya
author_sort E. M. Frantsiyants
collection DOAJ
description Pancreatic cancer (PC) is a lethal malignant tumor characterized by a rapid progression, invasiveness and resistance to radiochemotherapy. The development of biomarkers for the early diagnosis of the disease is relevant. Angiogenesis has been identified as a key factor in a number of pathological conditions, including cancer. The proangiogenic signaling molecule – vascular endothelial growth factor (VEGF) and its receptors play a central role in tumor angiogenesis. In this review, we also highlight the dual role of growth factor-β (TGF-β) and touch upon the prospects for therapeutic effects on targets associated with TGF-β signaling in pancreatic cancer. A growing interest is attracted to the role of insulin-like growth factors IGF-I and IGF-II in cancer diseases. IGF-I and its receptor are highly expressed on the surface of pancreatic cancer cell lines that initiate the transduction of intracellular signals associated with the proliferation, invasion and expression of angiogenesis mediators. And so, the study of markers and growth factors may be a new, viable option for the diagnosis and treatment of pancreatic cancer.
first_indexed 2024-04-10T01:26:12Z
format Article
id doaj.art-94f8d9e861624b9fa25d91c24ceadcd7
institution Directory Open Access Journal
issn 2410-1893
language Russian
last_indexed 2024-04-10T01:26:12Z
publishDate 2019-09-01
publisher QUASAR, LLC
record_format Article
series Issledovaniâ i Praktika v Medicine
spelling doaj.art-94f8d9e861624b9fa25d91c24ceadcd72023-03-13T09:35:00ZrusQUASAR, LLCIssledovaniâ i Praktika v Medicine2410-18932019-09-0163516410.17709/2409-2231-2019-6-3-5274BIOMARKERS, NEOANGIOGENESIS AND GROWTH FACTORS IN PANCREATIC CANCERE. M. Frantsiyants0O. I. Kit1V. I. Aleynov2I. A. Goroshinskaya3ФГБУ «Ростовский научно-исследовательский онкологический институт» Министерства здравоохранения Российской ФедерацииФГБУ «Ростовский научно-исследовательский онкологический институт» Министерства здравоохранения Российской ФедерацииФГБУ «Ростовский научно-исследовательский онкологический институт» Министерства здравоохранения Российской ФедерацииФГБУ «Ростовский научно-исследовательский онкологический институт» Министерства здравоохранения Российской ФедерацииPancreatic cancer (PC) is a lethal malignant tumor characterized by a rapid progression, invasiveness and resistance to radiochemotherapy. The development of biomarkers for the early diagnosis of the disease is relevant. Angiogenesis has been identified as a key factor in a number of pathological conditions, including cancer. The proangiogenic signaling molecule – vascular endothelial growth factor (VEGF) and its receptors play a central role in tumor angiogenesis. In this review, we also highlight the dual role of growth factor-β (TGF-β) and touch upon the prospects for therapeutic effects on targets associated with TGF-β signaling in pancreatic cancer. A growing interest is attracted to the role of insulin-like growth factors IGF-I and IGF-II in cancer diseases. IGF-I and its receptor are highly expressed on the surface of pancreatic cancer cell lines that initiate the transduction of intracellular signals associated with the proliferation, invasion and expression of angiogenesis mediators. And so, the study of markers and growth factors may be a new, viable option for the diagnosis and treatment of pancreatic cancer.https://www.rpmj.ru/rpmj/article/view/421рак поджелудочной железыбиомаркерыангиогенезvegfvegfrтрансформирующий фактор роста-βинсулиноподобный фактор роста
spellingShingle E. M. Frantsiyants
O. I. Kit
V. I. Aleynov
I. A. Goroshinskaya
BIOMARKERS, NEOANGIOGENESIS AND GROWTH FACTORS IN PANCREATIC CANCER
Issledovaniâ i Praktika v Medicine
рак поджелудочной железы
биомаркеры
ангиогенез
vegf
vegfr
трансформирующий фактор роста-β
инсулиноподобный фактор роста
title BIOMARKERS, NEOANGIOGENESIS AND GROWTH FACTORS IN PANCREATIC CANCER
title_full BIOMARKERS, NEOANGIOGENESIS AND GROWTH FACTORS IN PANCREATIC CANCER
title_fullStr BIOMARKERS, NEOANGIOGENESIS AND GROWTH FACTORS IN PANCREATIC CANCER
title_full_unstemmed BIOMARKERS, NEOANGIOGENESIS AND GROWTH FACTORS IN PANCREATIC CANCER
title_short BIOMARKERS, NEOANGIOGENESIS AND GROWTH FACTORS IN PANCREATIC CANCER
title_sort biomarkers neoangiogenesis and growth factors in pancreatic cancer
topic рак поджелудочной железы
биомаркеры
ангиогенез
vegf
vegfr
трансформирующий фактор роста-β
инсулиноподобный фактор роста
url https://www.rpmj.ru/rpmj/article/view/421
work_keys_str_mv AT emfrantsiyants biomarkersneoangiogenesisandgrowthfactorsinpancreaticcancer
AT oikit biomarkersneoangiogenesisandgrowthfactorsinpancreaticcancer
AT vialeynov biomarkersneoangiogenesisandgrowthfactorsinpancreaticcancer
AT iagoroshinskaya biomarkersneoangiogenesisandgrowthfactorsinpancreaticcancer